MedPath

The Serum Tissue Factor Level in Lung Cancer Patients as a Prognostic Factor

Conditions
Lung Cancer
Registration Number
NCT00257179
Lead Sponsor
National Taiwan University Hospital
Brief Summary

This study uses serum tissue factor and tissue factor inhibitor and factor VII to monitor the pre-coagulation status in lung cancer patients and to correlate the pre-coagulation status with clinical staging and prognosis.

Detailed Description

The staging of lung cancer was according to tumor size, involvement of lymph node and metastatic status. But there is a different prognosis in cancer patients of the same stage. The coagulation status of cancer patients was considered as an important possible prognostic factor. So in this study, we want to evaluate patients' coagulation status and find the relation of coagulation status and cancer status.

We thus propose a prospective study using coagulation factors in order to search for the relationship between cancer stage and pre-coagulation status in Taiwanese lung cancer patients. We will also evaluate the potential use of tissue factor as a prognosis predictor in lung cancer patients.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Patients with newly-diagnosed lung cancer
  • Serum from cancer-free healthy volunteers
Read More
Exclusion Criteria
  • Chronic renal failure or end-stage renal disease [ESRD] (creatinine [Cr] > 2 )
  • Hyperlipidemia on statin therapy
  • Acute myocardial infarction
  • Tapal or Plavix use
  • Active thromboembolic event
  • Severe liver disease (> child B)
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

National Taiwan University Hospital

🇨🇳

Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath